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Edited by Masayuki MiyasakaAbstract Anti-cytokine autoantibodies in healthy individuals
have been widely reported but the occurrence is variable and
inconstant. We hypothesized that cytokine-binding in vivo may
explain their variable and infrequent detection. Therefore, we fo-
cused on the detection of the cytokine-autoantibody complexes
and found that anti-cytokine autoantibody to IL-2, IL-8, tumor
necrosis factor-a, vascular endothelial growth factor and granu-
locyte-colony stimulating factor were present in all 15 individuals
evaluated, while those to IL-3, osteopontin and macrophage-col-
ony stimulating factor were not detected in anyone. Autoantibod-
ies against IL-4, IL-6, IL-10, and interferon-gamma were
variously detected. Thus, we discovered that anti-cytokine auto-
antibodies to multiple cytokines are ubiquitous in healthy individ-
uals.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Anti-cytokine autoantibodies are present in a number of
chronic inﬂammatory diseases [1,2], although a pathogenic
role has not been clariﬁed in most. In some instances, however,
anti-cytokine autoantibodies are believed to be central to
disease pathogenesis. For example, in some cases of Felty’s
syndrome, neutralizing autoantibodies against granulocyte-
colony stimulating factor (G-CSF) appear to mediate neutro-
penia [3]. In pulmonary alveolar proteinosis, autoantibodies
against granulocyte macrophage-colony stimulating factorAbbreviations: G-CSF, granulocyte-colony stimulating factor; GM-
CSF, granulocyte macrophage-colony stimulating factor; IVIG, phar-
maceutical intravenous human immunoglobulin; VEGF, vascular
endothelial growth factor; AutoAbVEGF, autoantibody against VEGF;
TNF-a, tumor necrosis factor-a; Biotin-VEGF, Biotinylated recombi-
nant human VEGF; Kav, average binding aﬃnity; OPN, osteopontin;
M-CSF, macrophage-colony stimulating factor; IFN-c, interferon-
gamma; ARDS, acute respiratory distress syndrome
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doi:10.1016/j.febslet.2007.04.029(GM-CSF), which eliminate GM-CSF bioactivity in vivo, ap-
pear to cause alveolar macrophage dysfunction, resulting in
impaired clearance of pulmonary surfactant, and respiratory
insuﬃciency [4–6].
Anti-cytokine autoantibodies have been reported to be read-
ily detected in some commercially available pharmaceutical
intravenous human immunoglobulin (IVIG) preparations
[7,8]. Anti-cytokine autoantibodies have also been detected, al-
beit rarely, in the sera of healthy individuals. For example, 1 in
300 individuals are positive for anti-cytokine antibodies by en-
zyme-linked immunosorbent assay (ELISA) [8] and 1 in 60
individuals are positive by radio-immuno assay [9]. The appar-
ent discrepancy might be explained by inclusion of individuals
with highly elevated levels of serum anti-cytokine autoantibod-
ies in the donor pool used for preparing commercial immuno-
globulin. Alternatively, anti-cytokine autoantibodies may be
present at low levels in the serum of most healthy individuals,
but in a poorly detectable form. In the present study, we
hypothesized that anti-cytokine autoantibodies are highly pre-
valent in healthy individuals and that formation of cytokine
autoantibody complexes in vivo impairs their detection by
commonly used immunological methods based on ligand spec-
iﬁcity. To elucidate this, we focused on the detection of cyto-
kine-autoantibody complex by a newly developed method.
We demonstrate the ubiquitous presence of anti-cytokine auto-
antibody in healthy individuals.2. Materials and methods
2.1. Study subjects
Healthy individual was deﬁned as one who did not have apparent
past history of disease including cancer, collagen disease, and infection
nor current episode of minor disease like common cold, allergy, and
fatigue for one month. Every participants underwent health checkup
annually. Eleven sera (male; n = 5, 30–51 y.o., female; n = 6, 20–49
y.o.), the three lots of fresh frozen plasma (FFP, Nisseki), and one
lot of IVIG (Venoglobulin-IH, Mitsubishi Pharma Corporation)
were analyzed.
2.2. Dissociation of cytokine-autoantibody complexes
Serum/plasma or IVIG was fractionated with polyethylene glycol
6000 in order to precipitate both immune complex and free IgG, and
to separate from free cytokines included in supernatant. The precipi-
tate was re-suspended in 10 mM TBS (pH 8.0) and subjected to protein
A/G column. Immunoglobulin G (IgG) was eluted with 100 mMation of European Biochemical Societies.
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The eluate was applied onto a spin column for ultraﬁltration (Micro-
con Centrifugal Filter Unit, Millipore, MW 100 kDa) and centrifuged
at 6000 · g in order to separate autoantibodies from autoantigens
smaller than the 100 kDa. Recovered IgG were dialyzed against
10 mM TBS (pH 8.0). Recovered autoantigens were dialyzed against
10 mM TBS (pH 8.0) in the presence of bovine serum albumin
(BSA), and concentrated with hygroscopic and high M.W. compound
(PIERCE). This procedure for dissociation of cytokine-autoantibody
complex was optimized by using vascular endothelial cell growth factor
(VEGF)-monoclonal anti-VEGF antibody complex model as shown in
supplementary data.
2.3. Isolation of autoantibody against VEGF (autoAbVEGF)
AutoAbVEGF in acidiﬁed and size-separated IVIG (pH 2.1) was iso-
lated with aﬃnity chromatography coupled with rhVEGF, and eluted
with 10 mM glycine–HCl/0.15 M NaCl (pH 2.1).
2.4. Immunoblotting
Cytokines (100 ng) were subjected to SDS–PAGE under reducing
conditions and transferred to polyvinylidene ﬂuoride membrane. The
membrane was blocked and hybridized with acidiﬁed-ultraﬁltrated
IgG fraction for 2 h. Bound IgG was detected with HRP-anti-human
IgG (Fab 0)2 and visualized with ECL plus (GE Healthcare).
2.5. ELISA
Binding speciﬁcity of isolated autoAbVEGF was examined on ELISA
plate pre-coated with cytokines, and determined by polymer-HRP-
anti-human IgG. Inhibitory binding assay was carried out by incubat-
ing with recombinant human VEGF (rhVEGF) or recombinant
human tumor necrosis factor-a (rhTNF-a) (ﬁnal 2.4 lg/mL) prior to
ELISA. IgG concentration of autoAbVEGF was measured by IgG assay
kit (PIERCE).
The concentration of G-CSF or macrophage-colony stimulating fac-
tor (M-CSF) was also measured by ELISA kit (Biosource and R&D,
respectively).
The occurrence of free anti-cytokine autoantibody in sera/plasma
was determined by ELISA plate pre-coated with cytokines followed
by detection with HRP-anti-human IgGF(ab 0)2. When the OD value
was higher than mean + 3S.D. of control level (cytokine not coated),
the results were determined as positive.
2.6. Saturation binding assay
Biotinylated recombinant human VEGF (Biotin-VEGF) was made
by NHS-PEO4-Biotin (PIERCE). AutoAbVEGF or control IgG
(humanized monoclonal anti-CD 20 antibody) was incubated with
Biotin-VEGF (0–26.2 nM), each solution including Biotin-VEGF-
autoAbVEGF complex was captured on ELISA plate pre-coated with
anti-human IgG, and detected with AP-streptavidin, and CDP-Star
with Sapphire-II Enhancer (Applied Biosystems). Based on a
Michaelis–Menten plot, average binding aﬃnity (Kav) was determined
from the concentration of free VEGF at 50% of the maximal binding.3. Results
3.1. Occurrence of cytokine-autoantibody complexes in healthy
individuals
We hypothesized that low or variable frequency in detection
of the anti-cytokine autoantibodies in healthy individuals is
due to the formulation of cytokine-autoantibody complex
in vivo. To evaluate this, we focused on detection of the com-
plex by a newly developed acidiﬁcation-ultraﬁltration proce-
dure described in Section 2. We ﬁrst evaluated the
occurrence of anti-cytokine autoantibodies in commercially
available IVIG preparations. Autoantibodies against VEGF,
interleukin (IL)-2 and IL-8 were not detected in free IgG but
were readily detected in the complex (Fig. 1A). We next eval-
uated the occurrence of the autoantibodies in serum/plasma
from disease-free, healthy human individuals. Similar to the re-sults with IVIG, autoantibodies against VEGF, IL-2 and IL-8
were readily detected in the complex but not in the free IgG
(Fig. 1B). Then, autoantibodies directed at other cytokines
were evaluated in the complex of serum/plasma of disease-free,
healthy human individuals using a series of cytokine ligands
for immunoblotting-based detection. Interestingly, all individ-
uals tested had autoantibodies against multiple diﬀerent cyto-
kines (Fig. 1C, Table 1). Of the 15 individuals evaluated, all
had autoantibodies against IL-2, IL-8, TNF-a, VEGF and
G-CSF, 14 had autoantibodies to IL-4, 11 had autoantibodies
to IL-10, and only 1 had antibodies to IL-6 or to interferon-
gamma (IFN-c). In contrast, no individuals had autoantibod-
ies to IL-3, osteopontin (OPN), or to M-CSF either with or
without acidiﬁcation-ultraﬁltration. None of the anti-cytokine
autoantibodies evaluated were detected in the free IgG of ser-
um/plasma samples (Table 1). These results demonstrate that
anti-cytokine autoantibody is ubiquitously present in the form
of cytokine-autoantibody complex in human serum and IVIG.
3.2. Binding speciﬁcity of autoAbVEGF
To establish the speciﬁcity of anti-cytokine autoantibodies
for their ligand targets, we ﬁrst isolated autoAbVEGF from
commercially available IVIG using the acidiﬁcation-ultraﬁltra-
tion step followed by VEGF-aﬃnity chromatography. Auto-
AbVEGF was highly speciﬁc for VEGF (Fig. 2A), using a
cytokine capture-based ELISA as we have previously use to
demonstrate the speciﬁcity of anti-cytokine antibodies [6]. Fur-
ther, soluble VEGF but not TNF-a signiﬁcantly inhibited the
detection of the autoantibody by ELISA (Fig. 2B). To further
characterize the autoAbVEGF, using a saturation binding plot
approach, we determined the Kav of aﬃnity-puriﬁed antibody
to be 2.9 nM (Fig. 2C). Thus, autoAbVEGF from the serum of
healthy individuals binds speciﬁcally to VEGF with moderate
aﬃnity.
3.3. Detection of bound ligand cytokines
While some cytokines (e.g., M-CSF) are readily detectable in
serum, others (G-CSF) are not or are present in very low abun-
dance. Hypothesizing that poorly detectable/low abundance
serum cytokines may be present in the form of immune com-
plexes and vice versa, we evaluated the acidiﬁed ultraﬁltrate
of human serum for the presence of M-CSF and G-CSF by
ELISA. The level of detectable G-CSF in the serum ultraﬁl-
trate was greatest when acidiﬁcation was performed at a pH
of 2.1 (Fig. 3A). Evaluation of serum from six individuals with
and without acidiﬁcation-ultraﬁltration revealed that G-CSF
in healthy human serum was completely bound to autoanti-
bodies making it undetectable in a standard capture ELISA
(Fig. 3B). Evaluation of M-CSF with and without acidiﬁcat-
ion-ultraﬁltration revealed that M-CSF was present in the
serum in a form not bound by autoantibody (Fig. 3C). Thus
M-CSF, a cytokine normally abundant in serum is not associ-
ated with anti-cytokine antibodies [10], while G-CSF, which is
normally poorly/not detectable [11] is present in only in the
form of complexes.4. Discussion
Our results show that the detection of anti-cytokine autoan-
tibodies in serum is hampered by binding to their respective
Fig. 1. Removal of the cytokine ligand improves detection of anti-cytokine autoantibodies in the serum of disease-free, healthy individuals. (A)
Immunoblotting to detect anti-cytokine autoantibodies in IVIG. (B) Immunoblotting to detect anti-cytokine autoantibodies in serum from healthy
human individuals. (C) Representative photographs of PVDF membrane showing protein staining with CBB (CBB) or immunoblotting (IB) to detect
autoantibodies for speciﬁc cytokines. (*) Human serum albumin coexisted with rIL-6. () Dimeric cytokine (IL-8, IL-10). () Thrombin-cleaved
N-terminal OPN (nOPN) coexisted with full length OPN (fOPN).
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abled us to detect cytokine-autoantibody complexes whichTable 1
Prevalence of anti-cytokine autoantibodies in disease-free, healthy
individuals
Cytokine Isoelectric point (pI) Acidiﬁcation-ultraﬁltration
no. positive (percent)
Not employed Employed
IL-2 6.60–6.83 0 (0) 15 (100)
IL-3 5.80–7.60 0 (0) 0 (0)
IL-4 9.42–9.90 0 (0) 14 (93.3)
IL-6 6.18–7.30 0 (0) 1 (6.7)
IL-8 5.00–7.85 0 (0) 15 (100)
IL-10 9.85–9.90 0 (0) 11 (73.3)
TNF-a 7.16–9.70 0 (0) 15 (100)
OPN 4.00 0 (0) 0 (0)
VEGF 6.40–7.30 0 (0) 15 (100)
G-CSF 5.50–6.10 0 (0) 15 (100)
M-CSF 4.68–4.70 0 (0) 0 (0)
IFN-c 10.20 0 (0) 1 (6.7)might have been always overlooked. The method made it pos-
sible to evaluate more accurate frequency of anti-cytokine
autoantibodies, and which resulted in the discovery that anti-
cytokine autoantibodies are ubiquitous in healthy individuals.
These observations have important implications for investiga-
tions regarding the pathological and potential physiological
roles of such autoantibodies in health and disease. Anti-cyto-
kine antibodies are present in autoimmune diseases, including
rheumatoid arthritis [1,2], acute respiratory distress syndrome
(ARDS) [12], Felty’s syndrome [3], and pulmonary alveolar
proteinosis [4–6]. Importantly, circulating immune complexes
comprised of autoantibody and cytokine ligands have been
demonstrated in some, e.g., IL-8 in ARDS [12], and GM-
CSF in pulmonary alveolar proteinosis [6]. Multiple reports
have suggested that anti-cytokine autoantibodies are infre-
quently present in healthy subjects [13–15]. However, the prev-
alence of anti-cytokine autoantibodies in healthy individuals
has been underestimated in previous reports. Surprisingly,
such autoantibodies were ubiquitous in healthy individuals, a
Fig. 2. Binding speciﬁcity of serum anti-VEGF autoantibodies isolated from IVIG. (A) Relative binding capacity of anti-VEGF autoantibody to
multiple other cytokines. Each values were compared with that to rhVEGF and expressed as percent binding. (B) Binding inhibition of anti-VEGF
autoantibody to recombinant VEGF with soluble cytokines. Relative binding capacity was expressed as percentage to control. (C) Saturation binding
plot of VEGF to anti-VEGF autoantibody. The average aﬃnity (Kav) was calculated on the basis of Michaelis–Menten’s theory.
Fig. 3. Quantiﬁcation of cytokines free in the serum and in the cytokine-antibody complexes. (A) G-CSF levels recovered with acidiﬁcation-
ultraﬁltration step with various acidic conditions were quantiﬁed by ELISA. (B, C) Levels of cytokines in the immune complex (Ab-bound) or in the
serum (Free). Each dot represents individual samples.
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viduals comprising a broad range of ages, genders, regions,
and cultures.The range of autoantibodies to diﬀerent cytokines varied
among healthy individuals. Autoantibodies against some cyto-
kines were present in all, while some were variably detected
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to speculate about the potential mechanistic signiﬁcance of
such diﬀerences in the presence of autoantibodies directed
against speciﬁc cytokines. It is possible that cytokines that
are normally abundant in serum (M-CSF, OPN) [10,16] may
have led to clonal elimination of lymphocytes directed against
these cytokines by thymic programing during development. As
a corollary, the presence of some anti-cytokine autoantibodies
might be explained by their lack of expression during develop-
ment and failure to eliminate the relevant clones. The variable
presence of some autoantibodies may reﬂect diﬀerences in
cytokine production among individuals, for example, due to
diﬀerences in immunological background or arising from dif-
ferences in prior microbial infection or allergen challenge.
Alternatively, a biophysical parameter of the cytokine, e.g.,
aﬃnity or property of its interaction with its anti-cytokine
autoantibody, e.g., conditions of optimal dissociation, may
be responsible for the diﬀerences. Reports have previously pro-
posed that anti-cytokine autoantibodies may limit the ‘down
stream’ movement of cytokines beyond the site of action, thus
preventing unwanted actions elsewhere [2,6]. Although future
studies will be required to determine, the consistent presence
of autoantibodies against G-CSF, IL-2, IL-8, TNF-a, and
VEGF in healthy individuals suggests their potential physio-
logical role in the regulation of biological activities of cyto-
kines. We assume that autoantibodies have three potential
roles. Firstly, they neutralize cytokines to regulate their bioac-
tivity [6]. Secondly, the cytokine-autoantibody complexes act
as reservoir for cytokines which elongates the half-life time
[17]. Lastly, per se, cytokine-autoantibody complexes them-
selves show bioactivities via Fcc receptor [12,18].
In conclusion, we found that most anti-cytokines autoanti-
bodies are forming cytokine-autoantibody complexes, and
are detected ubiquitously in the sera from normal subjects.
We believe that our discovery will contribute to better under-
standing of the autoantibodies as an important regulatory fac-
tor in the healthy subjects.
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